番茄社区app

Patient achieves remission with biologic agent currently used for myeloma

Having a medical condition was tied to increased risk of suicide in a dose-response-like manner

Systematic review and meta-analysis finds CAR T-cell-specific toxicities only account for 11.5%

Responses to pirtobrutinib observed in patients with previously treated disease

Results from some pulmonary function tests even showed improvement 3 years post-transplant

Better survival in one registry study, detriment with class I HLA mismatch in another

Pemivibart may have reduced activity against growing variant KP.3.1.1, agency warns

Findings from my recent study shook me to my core

News, features, and commentary about cancer-related issues

Axatilimab achieved a 75% response rate in patients with previously treated chronic GVHD

News, features, and commentary about cancer-related issues

New iteration of denileukin diftitox led to objective responses in 36% of pretreated patients

News, features, and commentary about cancer-related issues

Indicated for newly diagnosed patients who are eligible for stem cell transplant